These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23106853)

  • 1. OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines.
    Glogau R; Kane M; Beddingfield F; Somogyi C; Lei X; Caulkins C; Gallagher C
    Dermatol Surg; 2012 Nov; 38(11):1794-803. PubMed ID: 23106853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subject satisfaction with onabotulinumtoxinA treatment of glabellar and lateral canthal lines using a new patient-reported outcome measure.
    Rivers JK; Bertucci V; McGillivray W; Muhn C; Rosen N; Solish N; Weichman BM; Wheeler S; Daniels SR; Gallagher CJ
    Dermatol Surg; 2015 Aug; 41(8):950-9. PubMed ID: 26218728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin: examining duration of effect in facial aesthetic applications.
    Flynn TC
    Am J Clin Dermatol; 2010; 11(3):183-99. PubMed ID: 20369902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of Clinical Efficacy of OnabotulinumtoxinA in Crow's Feet Lines: Results from Two Multicenter, Randomized, Controlled Trials.
    Baumann L; Dayan S; Connolly S; Silverberg N; Lei X; Drinkwater A; Gallagher CJ
    Dermatol Surg; 2016 May; 42(5):598-607. PubMed ID: 27110893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.
    Carruthers J; Rivkin A; Donofrio L; Bertucci V; Somogyi C; Lei X; Davis PG; Campo A; Beddingfield FC
    Dermatol Surg; 2015 Jun; 41(6):702-11. PubMed ID: 25993609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint.
    Hanke CW; Narins RS; Brandt F; Cohen JL; Donofrio LM; Downie J; Heinz M; Harrington L; McDaniel DH; Nestor M; Schlessinger J; Schlöbe A; Taub A; Weiss RA
    Dermatol Surg; 2013 Jun; 39(6):891-9. PubMed ID: 23506308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subjective rating of cosmetic treatment with botulinum toxin type A: do existing measures demonstrate interobserver validity?
    Conkling N; Bishawi M; Phillips BT; Bui DT; Khan SU; Dagum AB
    Ann Plast Surg; 2012 Oct; 69(4):350-5. PubMed ID: 22964674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.
    Prager W; Rappl T
    J Cosmet Dermatol; 2012 Dec; 11(4):267-71. PubMed ID: 23174049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of OnabotulinumtoxinA Treatment of Forehead Lines: A Multicenter, Randomized, Dose-Ranging Controlled Trial.
    Solish N; Rivers JK; Humphrey S; Muhn C; Somogyi C; Lei X; Bhogal M; Caulkins C
    Dermatol Surg; 2016 Mar; 42(3):410-9. PubMed ID: 26863598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of incobotulinumtoxinA for treatment of glabellar frown lines: a post hoc pooled analysis of 2 randomized, placebo-controlled, phase 3 trials.
    Jones D; Carruthers J; Narins RS; Coleman WP; Harrington L; Brandt FS; Cohen JL
    Dermatol Surg; 2014 Jul; 40(7):776-85. PubMed ID: 25111351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results for incobotulinumtoxinA in the treatment of glabellar frown lines.
    Rzany B; Flynn TC; Schlöbe A; Heinz M; Harrington L
    Dermatol Surg; 2013 Jan; 39(1 Pt 1):95-103. PubMed ID: 23190342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Baumann L; Brandt FS; Kane MA; Donofrio LM
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S57-65. PubMed ID: 19945006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines.
    Moers-Carpi M; Dirschka T; Feller-Heppt G; Hilton S; Hoffmann K; Philipp-Dormston WG; Rütter A; Tan K; Chapman MA; Fulford-Smith A
    J Cosmet Laser Ther; 2012 Dec; 14(6):296-303. PubMed ID: 23057624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a novel botulinum toxin type A product for the treatment of moderate to severe glabellar lines: a randomized, double-blind, active-controlled multicenter study.
    Won CH; Lee HM; Lee WS; Kang H; Kim BJ; Kim WS; Lee JH; Lee DH; Huh CH
    Dermatol Surg; 2013 Jan; 39(1 Pt 2):171-8. PubMed ID: 23301821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pooled Subject-Reported Outcomes From 2 Phase 3 Studies of OnabotulinumtoxinA for Simultaneous Treatment of Forehead and Glabellar Lines.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Larsen KE; Varon S; Garcia JK
    Dermatol Surg; 2020 Jul; 46(7):950-957. PubMed ID: 31567611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OnabotulinumtoxinA for Treatment of Forehead and Glabellar Lines: Subject-Reported Satisfaction and Impact From a Phase 3 Double-Blind Study.
    Ogilvie P; Rivkin AZ; Dayan S; Yoelin SG; Weichman BM; Garcia JK
    Dermatol Surg; 2019 May; 45(5):689-699. PubMed ID: 31034447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A four-month randomized, double-blind evaluation of the efficacy of botulinum toxin type A for the treatment of glabellar lines in women with skin types V and VI.
    Grimes PE; Shabazz D
    Dermatol Surg; 2009 Mar; 35(3):429-35; discussion 435-6. PubMed ID: 19250310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 3 Study of OnabotulinumtoxinA Distributed Between Frontalis, Glabellar Complex, and Lateral Canthal Areas for Treatment of Upper Facial Lines.
    De Boulle K; Werschler WP; Gold MH; Bruce S; Sattler G; Ogilvie P; Street J; Larsen KE; Yushmanova I; Lei X; Lee E; Vitarella D; Mao C
    Dermatol Surg; 2018 Nov; 44(11):1437-1448. PubMed ID: 30096106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Patient Satisfaction for up to 6 Months With OnabotulinumtoxinA Treatment for Upper Facial Lines.
    Cohen JL; Fagien S; Ogilvie P; De Boulle K; Carruthers J; Cox SE; Kelly R; Garcia JK; Sangha S
    Dermatol Surg; 2022 Nov; 48(11):1191-1197. PubMed ID: 36342250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, Efficacy, and Patient Satisfaction With OnabotulinumtoxinA for the Treatment of Upper Facial Lines in Japanese Subjects.
    Kawashima M; Harii K; Horiuchi Y; Seidman E; Lei X; Hopfinger R; Lee E
    Dermatol Surg; 2020 Apr; 46(4):483-490. PubMed ID: 31517663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.